On the public citation graph
Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
0 signed · 41 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2019.3241openalex-snapshot
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
inferredcites →https://doi.org/10.1001/jamaoncol.2019.1549openalex-snapshot
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
inferredcites →https://doi.org/10.1002/advs.202003263openalex-snapshot
Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
inferredcites →https://doi.org/10.1002/cam4.2014openalex-snapshot
Real‐world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non‐driver gene mutation advanced non‐small cell lung cancer
inferredcites →https://doi.org/10.1002/cam4.2256openalex-snapshot
What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China
inferredcites →https://doi.org/10.1016/j.ebiom.2019.03.023openalex-snapshot
Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
inferredcites →https://doi.org/10.1016/j.jtho.2017.12.001openalex-snapshot
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
inferredcites →https://doi.org/10.1016/s0140-6736(16)31473-8openalex-snapshot
New and emerging targeted treatments in advanced non-small-cell lung cancer
inferredcites →https://doi.org/10.1038/nmeth.4514openalex-snapshot
NetSig: network-based discovery from cancer genomes
inferredcites →https://doi.org/10.1038/nrc.2017.84openalex-snapshot
Understanding and targeting resistance mechanisms in NSCLC
inferredcites →https://doi.org/10.1093/bioinformatics/btq170openalex-snapshot
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
inferredcites →https://doi.org/10.1111/cas.14032openalex-snapshot
Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
inferredcites →https://doi.org/10.1126/science.aat7171openalex-snapshot
Minimal functional driver gene heterogeneity among untreated metastases
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-0225openalex-snapshot
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
inferredcites →https://doi.org/10.1186/s13059-016-0893-4openalex-snapshot
deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution
inferredcites →https://doi.org/10.1186/s13073-017-0424-2openalex-snapshot
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
inferredcites →https://doi.org/10.1200/jco.2007.15.0375openalex-snapshot
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1517/14712598.2013.827657openalex-snapshot
Targeted therapy for NSCLC with driver mutations
inferredcites →https://doi.org/10.1634/theoncologist.2018-0572openalex-snapshot
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer
inferredcites →https://doi.org/10.2147/copd.s167372openalex-snapshot
Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients
inferredcites →https://doi.org/10.6004/jnccn.2018.0062openalex-snapshot
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
inferredcites →https://doi.org/10.7150/jca.27490openalex-snapshot
Lung cancer in young adults aged 35 years or younger: A full-scale analysis and review
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4802669openalex-extracted
Lactobacillus Paracasei JN-8 Produces Genistein and Elicits Anti-Tumor Capacity
inferred← citeshttps://doi.org/10.1002/cac2.12227openalex-snapshot
Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
inferred← citeshttps://doi.org/10.1002/ijc.70075openalex-snapshot
Comparisons of blood, upper respiratory tract and gut viromes from patients with lung cancer and healthy persons
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2023.122365openalex-snapshot
Synchronized activating therapeutic nano-agent: Enhancement and tracing for hypoxia-induced chemotherapy
inferred← citeshttps://doi.org/10.1016/j.lungcan.2023.107439openalex-snapshot
Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.05.025openalex-snapshot
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?
inferred← citeshttps://doi.org/10.1016/j.semcancer.2022.02.018openalex-snapshot
Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.tranon.2024.102143openalex-snapshot
Spatial heterogeneity of infiltrating immune cells in the tumor microenvironment of non-small cell lung cancer
inferred← citeshttps://doi.org/10.1136/jitc-2022-005436openalex-snapshot
Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
inferred← citeshttps://doi.org/10.1186/s13000-023-01401-0openalex-snapshot
DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
inferred← citeshttps://doi.org/10.1245/s10434-023-14249-xopenalex-snapshot
Comprehensive Multiomics Analyses Establish the Optimal Prognostic Model for Resectable Gastric Cancer
inferred← citeshttps://doi.org/10.21037/tcr-21-1841openalex-snapshot
Analysis of prognostic and therapeutic values of drug resistance-related genes in the lung cancer microenvironment
inferred← citeshttps://doi.org/10.21037/tcr-21-2395openalex-snapshot
Ryanodine receptor (RYR) mutational status correlates with tumor mutational burden, age and smoking status and stratifies non-small cell lung cancer patient prognosis
inferred← citeshttps://doi.org/10.21037/tcr-21-240openalex-snapshot
Mutational status of main driver genes influences the prognosis of stage I–III lung adenocarcinoma patients underwent radical surgery
inferred← citeshttps://doi.org/10.2147/cmar.s384918openalex-snapshot
Mutational and Transcriptional Characterization Establishes Prognostic Models for Resectable Lung Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.21873/cdp.10166openalex-snapshot
A Malignant Tumor Developed Seven Years After Small Cell Lung Cancer Treated With Etoposide-containing Chemotherapy
inferred← citeshttps://doi.org/10.3389/fonc.2021.708294openalex-snapshot
DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer
inferred← citeshttps://doi.org/10.3389/fonc.2021.713853openalex-snapshot
Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
showing the first 18 of 19 · page through all 19
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.